Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma

Toshiya Kamiyama1*, Kazuaki Nakanishi2, Hideki Yokoo1, Hirofumi Kamachi2, Munenori Tahara1, Tatsuhiko Kakisaka1, Yosuke Tsuruga1, Satoru Todo2 and Akinobu Taketomi1

Abstract

Background: Liver resection for hepatocellular carcinoma (HCC) has the highest local controllability among all local treatments and results in a good survival rate. However, the recurrence rates of HCC continue to remain high even after curative hepatectomy. Moreover, it has been reported that some patients with HCC have an early death due to recurrence. We analyzed the preoperative risk factors for early cancer death.

Methods: Between 1997 and 2009, 521 consecutive patients who underwent hepatectomy for HCC at our center were assigned to group ED (death due to HCC recurrence or progression within 1 year after hepatectomy) and group NED (alive over 1 year after hepatectomy). Risk factors for early cancer death were analyzed.

Results: Group ED included 48 patients, and group NED included 473 patients. The cause of death included cancer progression (150; 78.1%), operation-related (1; 0.5%), hepatic failure (15; 7.8%), and other (26; 13.5%). Between the ED and NED groups, there were significant differences in albumin levels, Child-Pugh classifications, anatomical resections, curability, tumor numbers, tumor sizes, macroscopic vascular invasion (portal vein and hepatic vein), alpha-fetoprotein (AFP) levels, AFP-L3 levels, protein induced by vitamin K absence or antagonism factor II (PIVKA-II) levels, differentiation, microscopic portal vein invasion, microscopic hepatic vein invasion, and distant metastasis by univariate analysis. Multivariate analysis identified specific risk factors, such as AFP level > 1,000 ng/ml, tumor number ≥ 4, tumor size ≥ 5 cm, poor differentiation, and portal vein invasion. With respect to the preoperative risk factors such as AFP level, tumor number, and tumor size, 3 (1.1%) of 280 patients with no risk factors, 12 (7.8%) of 153 patients with 1 risk factor, 24 (32.9%) of 73 patients with 2 factors, and 9 (60.0%) of 15 patients with 3 risk factors died within 1 year of hepatectomy (p < 0.0001).

Conclusions: Hepatectomy should be judiciously selected for patients with AFP level > 1,000 ng/ml, tumor number ≥ 4, and tumor size ≥ 5 cm, because patients with these preoperative risk factors tend to die within 1 year after hepatectomy; these patients might be better treated with other therapy.

Keywords: Hepatocellular carcinoma, Hepatectomy, Early death

* Correspondence: t-kamiya@med.hokudai.ac.jp
1The Department of General Surgery, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan
Full list of author information is available at the end of the article

© 2012 Kamiyama et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Liver resection for the treatment of hepatocellular carcinoma (HCC) has the highest controllability among all local treatments and results in a good survival rate [1,2]. However, recurrence rates remain high and are the main cause of early death even after curative hepatectomy [3]. Moreover, it has been reported that some patients with HCC have an early death due to recurrence [4]. In the remnant liver after hepatectomy, tumor recurrence is recognized as intrahepatic metastasis caused by dissemination of cells in the portal vein or metachronous multicentric hepatocarcinogenesis [5]. The risk factors for early recurrence are reported to be related to tumor cell dissemination due to tumor characteristics such as vascular invasion [6,7] and intrahepatic metastasis [8]. Though the two algorithms that were proposed from the Barcelona Clinic Liver Cancer (BCLC) classification [9] and Japanese guideline [10] recommend that multiple HCCs be treated by transcatheter arterial chemoembolization with lipiodol (TACE) or sorafenib, hepatectomy beyond these algorithms was actually performed in the clinical scene. However, the risk factors for early death due to HCC recurrence or progression within 1 year after hepatectomy have not been clearly evaluated [11].

On the other hand, the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial [12] recently reported the effectiveness of sorafenib in the treatment of advanced HCC. In this report, median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group. If patients have an early death within 1 year due to recurrence after hepatectomy, there might be no benefit of hepatectomy compared to sorafenib. Therefore, the risk factors for early death within 1 year after hepatectomy due to HCC recurrence or progression should be evaluated, and the appropriateness of hepatectomy for patients with advanced HCC should be investigated.

To identify the risk factors related to early death after hepatectomy, we analyzed the outcomes of 521 consecutive patients who underwent primary hepatectomy for HCC at our center.

Methods
Patients
Between January 1997 and May 2009, 521 consecutive patients underwent hepatectomy for HCC at our center. These patients were followed for at least 1 year, and then assigned to group ED (death due to HCC recurrence or progression within 1 year after hepatectomy) or group NED (alive over 1 year after hepatectomy). The resulting ED group included 48 (9.2%) patients, and the resulting NED group included 465 (89.3%) patients. Of all 521 patients, 8 (1.5%) patients who died of liver failure, other causes, and postoperative complications within 1 year after hepatectomy were excluded from group ED and NED. The mean age of 513 patients of group ED and NED was 61.3 years, with a range of 18–87 years. Of the 513 patients, 427 (83.2%) were male and 86 (16.8%) were female, 221 (43.1%) were hepatitis B virus surface antigen-positive, 189 (36.8%) were hepatitis C virus antibody-positive, and 175 (34.1%) had cirrhosis. At least 2 weeks before hepatectomy, imaging studies were performed and preoperative serum alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3), and protein induced by vitamin K absence or antagonism factor II (PIVKA-II) levels were simultaneously measured using standard methods. Among the 513 patients, 499 (97.3%) were categorized as Child-Pugh class A (Table 1). The patients were followed up for a median of 84.2 months (range, 12.5–165.0 months). This study was approved by the Institutional Review Board of the Hokkaido University, School of Advanced Medicine.

Hepatectomy
Anatomical resection is defined as a resection in which lesion(s) are completely removed anatomically on the basis of Couinaud’s classification (segmentectomy, sectionectomy, and hemihepatectomy or extended hemihepatectomy) in patients with sufficient functional reserve. Non-anatomical partial resection was performed as a limited resection or tumor enucleation. When R0 resections were performed, the resection surface was found to be histologically free of HCC. Indocyanine green retention rates at 15 min (ICGR15) were measured to evaluate liver function reserve, regardless of the presence or absence of cirrhosis.

HCC recurrence
Every 3 months for the first 2 years after hepatectomy, the patients underwent follow-up evaluations comprising liver function tests, measurements of tumor markers AFP and PIVKA-II, ultrasonography (US), and dynamic computed tomography (CT). After 2 years, routine CT was performed only once every 4 months. If recurrence was suspected, CT and magnetic resonance imaging (MRI) were performed; if necessary, CT during angiography and bone scintigraphy were also performed. This enabled precise diagnoses of the site, number, size, and invasiveness of the recurrent lesions.

Statistical analysis
Patient survival (PS) rates were determined via the Kaplan-Meier method. Univariate analysis was performed; then multivariate analysis and logistic regression were performed only on significant variables. Statistical analyses (StatView 5.0 for Windows: SAS Institute Inc., Cary, NC) were performed using standard tests (X^2, t-test) where appropriate. Significance was defined as p < 0.05.
Results

Causes of death

PS rates ($n = 521$) at 1, 2, 5, and 10 years were 90.5%, 84.6%, 69.0%, and 54.2%, respectively (Figure 1), with 192 deaths (36.9%). The causes of death, whether within 1 year post-hepatectomy or later, included HCC recurrence or progression ($n = 150; 78.1%$), liver failure ($n = 15; 7.8%$), other causes ($n = 26; 13.5%$), and postoperative complications ($n = 1; 0.5%$). Of the 150 patients who died of HCC recurrence or progression, 48 (32.0%) died within 1 year after hepatectomy (Figure 2). The patients who died of liver failure ($n = 4$), other causes ($n = 3$), and postoperative complications ($n = 1$) within 1 year after hepatectomy were excluded from group ED and NED.

Clinicopathological characteristics and operative variables

Patient characteristics and perioperative outcomes are shown in Table 1. Between the ED and NED groups,
there were significant differences in albumin levels, Child-Pugh classifications, anatomical resections, curability, tumor numbers, tumor sizes, macroscopic vascular invasion (portal vein and hepatic vein), AFP levels, AFP-L3 levels, PIVKA-II levels, differentiation, microscopic portal vein invasion, microscopic hepatic vein invasion, and distant metastasis. Tumor-related factors are also shown in Table 1. When the risk factors that were identified as significant by univariate analysis were included in a multivariate analysis via logistic regression, it was found that AFP level, tumor number, tumor size, differentiation, and microscopic portal vein invasion were independent risk factors for early death due to HCC recurrence or progression within 1 year after hepatectomy (Table 2).

### Discussion

When the patients were categorized by the number of independent, preoperatively evaluable risk factors, the

| No. of patients | No. of ED (%) | Risk ratio 95% CI |
|-----------------|---------------|------------------|
| Risk 0          | 276           | 3 (1.1)          | 1                |
| Risk 1          | 151           | 12 (7.9)         | 7.856            |
| Risk 2          | 71            | 24 (33.8)        | 46.468           |
| Risk 3          | 15            | 9 (60.0)         | 136.5            |

HCC: hepatocellular carcinoma.
ED: death due to HCC recurrence or progression within 1 year after hepatectomy.
Risk 0: they had no risk factors.
Risk 1: they had any one risk factor.
Risk 2: they had any two risk factors.
Risk 3: they had all three risk factors.
Risk factors: AFP > 1,000 ng/ml, tumor number ≥4, and tumor size ≥5 cm.
early death rate within 1 year was 60.0% for patients with three risk factors: AFP > 1,000 ng/ml, tumor number ≥ 4, and tumor size ≥ 5 cm, while the early death rate was 1.1% for patients with no risk factors. Therefore, the appropriateness of heptectomy for HCC should be carefully examined for patients who have large and multiple HCC with high AFP levels; these patients might be better treated with other therapeutic options, such as TACE or sorafenib.

Early recurrence is the main cause of early death within 1 year after heptectomy. The risk factors for early recurrence are reported to be related to tumor cell dissemination due to tumor characteristics such as vascular invasion [6,7] and intrahepatic metastasis [8]. Because these factors are diagnosed only by postoperative pathological examination, preoperatively evaluable factors are necessary to decide the appropriateness of heptectomy in advanced HCC. Among preoperatively risk factors, an HCC tumor larger than 5 cm is reported to be an important indicator of a high risk of recurrence after resection [13] and has a higher incidence of intrahepatic metastasis and portal venous invasion [14,15]. Therefore, it is believed that an HCC tumor larger than 5 cm has high malignant potential. In this study and another report [11], tumor size ≥ 5 cm reflected this high malignant potential and was selected as an independent risk factor for early death due to HCC recurrence or progression within 1 year after heptectomy.

Multivariate analysis also shows that tumor number is an important predictor of recurrence. Lai et al. [16] reported that the presence of multiple nodules was the most powerful predictor of both long-term survival and tumor recurrence. Because multiple HCC originates from disseminated cancer cells and not from multicentric carcinogenesis, multiple HCC is a more aggressive phenotype than solitary HCC. Yang reported that, after resection of solitary large HCC, the clinical and pathological characteristics and outcome are similar to those of small HCC, but are significantly better than those of nodular HCC (node number ≥ 2) [17]. It has also been reported that the expression levels of some human genes closely related to invasion and metastasis were significantly lower in solitary large HCC than in nodular HCC [17,18]. They proposed solitary large HCC as a specific subtype, less malignant than nodular HCC. Moreover, in multiple HCC, it was speculated that latent tumors, intrahepatic micrometastases that might be subsequently found to produce early recurrent tumors, could already be present in the remnant liver at the time of surgery. Therefore, tumor number ≥ 4 was selected in the current study as a significant factor predicting early death after heptectomy.

In our study, multivariate analysis showed that an AFP level over 1,000 ng/ml was an independent factor related to early death. Previous reports have shown that AFP is an independent predictor of prognosis [19], even in patients who had undergone heptectomy [20]. High levels of AFP in fully developed HCC or in the serum of the host are associated with more aggressive behavior and increased anaplasis [21]. On the other hand, it is well known that AFP levels may increase in some patients with acute and chronic hepatitis without HCC [22,23] and that elevation of AFP levels correlates with inflammation caused by background diseases and hepatocyte regeneration [24]. However, because the elevation of AFP levels by hepatitis or regeneration is usually not so high, only 200 ng/ml [25], AFP levels over 1,000 ng/ml might specifically indicate tumor malignancy. Yamanaka et al. [26] also reported that the serum AFP value per tumor diameter was the most significant risk factor for early death within 1 year after resection in patients with stage II–III HCC by multivariate analysis.

Given these preoperatively evaluable risk factors, the probability of early death after heptectomy can be estimated by the number of risk factors. In risk 0, 3 patients (1.1%), in risk 1, 12 patients (7.9%), in risk 2, 24 patients (33.8%), and in risk 3, 9 patients (60.0%) died within 1 year after heptectomy. The risk ratio of risk 1 vs. risk 0 was 7.856, that of risk 2 vs. risk 0 was 46.468, and that of risk 3 vs. risk 0 was 136.5 by multivariate analysis. PS rates for risk 3 at 1 year were 40.0%, while in the SHARP trial, survival rates at 1 year were 44% in the sorafenib group [12]. Moreover, Takayasu et al. reported that the survival rate at 1 year of patients with ≥ 4 tumors, ≥ 1 cm in diameter was 74% [27]. In this way, because the surgical outcome of patients with all three risk factors was worse than that of the patients treated with sorafenib or TACE, these patients might be better treated with other therapeutic options than heptectomy for the first
line treatment. However, selected patients with risk 1 and 2 who might be beyond BCLC and Japanese algorithms should not be excluded from hepatectomy because of their good outcome: 91.7%, 66.1% at 1 year of PS.

On the other hand, in this study, macroscopic vascular invasion (portal and hepatic veins) was not indicated by multivariate analysis as an independent risk factor related to early death. It has been reported that the prognosis of patients with portal vein tumor thrombus (PVTT) in the main trunk or first branch is very poor; the median survival period of patients with portal thrombosis is only 2.7 months without appropriate treatment [28]. However, recently reported patients showed long-term survival rates when hepatectomy was combined with pre- or postoperative treatment. We reported the efficacy of a combination of hepatectomy and preoperative radiotherapy for PVTT in the main trunk or first branch. The 1-, 3-, and 5-year survival rates in hepatectomized patients with preoperative radiotherapy for PVTT were 100%, 53.3%, and 40.0%, respectively [29]. Minagawa [30] reported that the survival rate of patients with PVTT, including those who underwent hepatic resection with preoperative transcatheter arterial chemotherapy, was 42% at 5 years. Nagano [31] reported that 15 patients with HCC with PVTT were treated with FU arterial infusion and interferon therapy (FAIT) and surgery, and that all the patients (100%) survived over 1 year; without FAIT and surgery, 10 patients (67%) died within 1 year. Therefore, even if patients have HCC with macroscopic vascular invasion, particularly PVTT in the main trunk or first branch, hepatectomy is not contraindicated in these patients when combined with pre- or postoperative treatment. In the patients with risk 0, 1, of 45 patients 19 had macroscopic vascular invasion. Of these 19 patients, only 5 (26.3%) died within 1 year after hepatectomy. In the 26 patients with risk 2, 3, 15 patients (57.7%) died within 1 year after hepatectomy. Concerning Child-Pugh B cirrhosis, the high-risk patients could be also indentified. From these data, despite macroscopic vascular invasion and Child-Pugh B cirrhosis were poor prognostic factors, the patients who had these factors did not always die in 1 year after hepatectomy. Using our risk levels, the patients with extremely poor prognosis could be identified from the patients who had poor prognostic factors such as macroscopic vascular invasion or Child-Pugh B. Therefore, concerning risk levels, risk 0 to 3 was very important and useful for predicting the prognosis of patients with HCC who underwent hepatectomy.

Conclusions

In conclusion, the appropriateness of hepatectomy in the treatment of HCC should be carefully considered when patients have the following preoperative risk factors: AFP > 1,000 ng/ml, tumor number ≥ 4, and/or tumor size ≥ 5 cm; these patients might be better treated with other therapeutic options, i.e., sorafenib and TACE. However, even if patients have HCC with PVTT in the main trunk or first branch, hepatectomy is not contraindicated when combined with pre- or postoperative treatment.

Abbreviations

HCC: Hepatocellular carcinoma; PS: Patient survival; KGR15: Indocyanine green retention rate at 15 min; AFP: Alpha-fetoprotein; AFP-L3: Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein-L3 fraction; PIMA-II: Protein induced by vitamin K absence or antagonism factor II; US: Ultrasonography; CT: Computed tomography; MRI: Magnetic resonance imaging; TACE: Transcatheter arterial chemoembolization.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

The authors wish to thank the staff of General Surgery, Graduate School of Medicine, Hokkaido University, for their kind cooperation.

Author details

1The Department of General Surgery, Hokkaido University Graduate School of Medicine, North 15, West 7, Kitaku, Sapporo 060-8638, Japan. 2The Department of Transplantation Surgery, Hokkaido University Graduate School of Medicine, North 15, West 7, Kitaku, Sapporo 060-8638, Japan.

Authors’ contributions

TK designed the research; TK, KN, and HY acquired of the data; TK, KN, HY, HK, TK, YT, ST, and AT analyzed the data; TK wrote the paper. All authors read and approved the final manuscript.

Received: 7 March 2012 Accepted: 14 June 2012
Published: 14 June 2012

References

1. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000, 32:1224–1229.
2. Hasegawa K, Kokudo N, Imamura H, Matsuura Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M: Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005, 242:252–259.
3. Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Suzuki T, Shimamura T, Fukunaga H, Matsushita M, Todo S: Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol 2009, 16:1560–1571.
4. Kondo K, Chihiwa K, Makino I, Kai M, Maehara N, Ouchida J, Nagamuro S: Risk factors for early death after liver resection in patients with solitary hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2005, 12:399–404.
5. Adachi E, Maeda T, Matsumata T, Shisube K, Kinukawa N, Sugimachi K, Tsuneyoshi M: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995, 108:768–775.
6. Imamura H, Matsuuma Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200–207.
7. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000, 89:500–507.
8. Iikeda Y, Kajiyama K, Adachi E, Yamagata M, Shimada M, Yanaga K: Early recurrence after surgery of hepatocellular carcinoma. Hepatogastroenterology 1995, 42:469–472.
9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepato 2001, 35:421–430.

10. Makuchii M, Kokuo N, Arii S, Futagawa S, Kameko S, Kawanaka S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saiga Y, Takayama T, Yamaoka Y: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008, 38:37–51.

11. Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, Ikai I, Yamaoka Y, Belghiti J: Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol 2004, 85:36–41.

12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forster A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Silver HK, Gold P, Shuster J, Javitt NB, Freedman SO, Finlayson ND: Occurrence of alpha-fetoprotein in acute viral hepatitis. Cancer 1971, 28:129–132.

13. Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, Taylor BR, Grant DF, Vollmer CM: Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 2006, 202:275–283.

14. Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, Tsuneyoshi M: Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 1996, 77:2022–2031.

15. Kosuge T, Makuchii M, Takayama T, Yamamoto J, Shimada K, Yamasaki S: Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology 1993, 40:328–332.

16. Lai EC, You LT, Nig RO, Shek TW: The pathological basis of resection margin for hepatocellular carcinoma. World J Surg 1993, 17:790, discussion 91.

17. Yoshida M, Waki M, Wajima K, Obara M, Suzuki S, Kato K, Itoh H, Hasegawa M, Tanaka Y, Ido Y: A clinicopathological study of resected hepatocellular carcinoma with poor prognosis. Hepatology 2004, 39:2193–2197.

18. Nakamura M, Makuchii M, Takayama T, Ohtomo K: Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001, 233:379–384.

19. Yamanaka J, Yamanaka N, Nakajima K, Nakaoka T, Takahara M, Nagakawa T, Takami H, Tsuchida T, Matsuura M, Todo S: Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. Jpn J Clin Oncol 2007, 37:363–368.

20. Minagawa M, Makuchii M, Takayama T, Ohtomo K: Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Hepatogastroenterology 2007, 54:172–179.

21. Matsumoto Y, Suzuki T, Asada I, Ozawa K, Tobe T, Honjo I: Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 1996, 77:2022–2031.

22. Smith JB: Alpha-fetoprotein in chronic liver disease. Cancer 1989, 64:1700–1707.

23. Inoue K, Kajigasa S, Ikeda N, Adachi W, Arano J: Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C virus infection: univariate and multivariate analysis. Am J Gastroenterol 2001, 96:1243–1250.

24. Matsumoto Y, Suzuki T, Asada I, Ozawa K, Tobe T, Honjo I: Clinical classification of hepatoma in Japan according to serial changes in serum alpha-fetoprotein levels. Cancer 1982, 49:354–360.

25. Smith JB: Occurrence of alpha-fetoprotein in acute viral hepatitis. Int J Cancer 1971, 4:421–424.

26. Silver HK, Gold P, Shuster J, Javitt NB, Freedman SO, Finnayson ND: Alpha(1) -fetoprotein in chronic liver disease. N Engl J Med 1974, 291:506–508.

27. Fujisawa S, Tanaka M, Maeda S, Ashihara H, Hirata R, Toritani K: Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002, 62(Suppl 1):57–63.

28. Luk AS, Lai CL: Alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989, 9:110–115.

29. Yamamoto K, Yamakawa K, Kuroda N, Kuroda N, Takata M, Tani T, Yanai C, Kuroda N, Takata M, Maeda S, Matsukuma K, Sugimachi K, Okamoto E: Clinicopathologic analysis of stage II–III hepatocellular carcinoma showing early massive recurrence after liver resection. Gastroenterol Hepatol 2000, 15:1192–1198.

30. Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuoka Y, Sakamoto M, Nakashima K, Kudo Y, Kuroko N, Makuchii M: Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012, 56:886–892.

31. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62–67.

32. Kamiyama T, Nakanishi K, Yokoh K, Tahara M, Nakagawa T, Kamachi H, Takata M, Hirato H, Matsuoka K, Todo S: Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. Jpn J Clin Oncol 2007, 37:363–368.